Analyst Price Target is $24.25
▲ +156.61% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Repare Therapeutics in the last 3 months. The average price target is $24.25, with a high forecast of $30.00 and a low forecast of $14.00. The average price target represents a 156.61% upside from the last price of $9.45.
Current Consensus is
Buy
The current consensus among 5 investment analysts is to buy stock in Repare Therapeutics. This Buy consensus rating has held steady for over two years.
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Read More